

AMENDMENTS TO THE CLAIMS

1-79. (Cancelled)

80. (New) A method for inhibiting inflammation comprising, administering to a subject having an inflammatory disorder selected from the group consisting of asthma, gastrointestinal inflammation, pulmonary inflammation, kidney inflammation, ocular inflammation, pancreatic inflammation, genitourinary inflammation, systemic lupus erythematosus, dermatomyocytis, polymyositis, inflammatory neuropathies, Wegoner's granulomatosis, polyarteritis nodosa, polymyalgia, rheumatica, temporal arteritis, Sjorgren's syndrome, Bechet's disease, Churg-Strauss syndrome, Takayasu's arteritis, neuroinflammatory disorders, allergic inflammation, dermatological inflammation, and skeletal inflammation, inflammation from infection, an amount of a heterocyclic microsomal triglyceride transfer protein (MTP) inhibitor effective to inhibit the inflammation.

81. (New) The method of claim 80, wherein the inflammatory disorder is asthma.

82. (New) The method of claim 80, wherein the inflammatory disorder is gastrointestinal inflammation.


83. (New) The method of claim 80, wherein the inflammatory disorder is pulmonary inflammation.

84. (New) The method of claim 80, wherein the inflammatory disorder is kidney inflammation.


85. (New) The method of claim 80, wherein the inflammatory disorder is ocular inflammation.


86. (New) The method of claim 80, wherein the inflammatory disorder is pancreatic inflammation.


87. (New) The method of claim 80, wherein the inflammatory disorder is inflammatory neuropathy.
88. (New) The method of claim 80, wherein the inflammatory disorder is genitourinary inflammation.
89. (New) The method of claim 80, wherein the inflammatory disorder is systemic lupus erythematosus, dermatomyocytis, Wegoner's granulomatosus, polyarteritis nodosa, polymyalgia, rhuematica, temporal ateritis, Sjorgren's syndrome, Bechet's disease, Churg-Strauss syndrome, or Takayasu's arteitis.
90. (New) The method of claim 80, wherein the inflammatory disorder is polymyositis.
91. (New) The method of claim 80, wherein the inflammatory disorder is a neuroinflammatory disorder.
92. (New) The method of claim 80, wherein the inflammatory disorder is allergic inflammation.
93. (New) The method of claim 80, wherein the inflammatory disorder is dermatological inflammation.
94. (New) The method of claim 80, wherein the inflammatory disorder is skeletal inflammation.
95. (New) The method of claim 80, wherein the inflammatory disorder is inflammation from infection.
96. (New) The method of claim 80, wherein said MTP inhibitor is a compound according to Formula I:



wherein n is zero or 1;


P is  or a 5- or 6- membered heterocycle selected from the group consisting of:







wherein T and U are, independently, hydrogen or lower alkyl.


97. (New) The method of claim 80, wherein said MTP inhibitor is a compound according to Formula I:



wherein n is zero or 1;


P is  or a 5- or 6- membered heterocycle selected from the group consisting of:





wherein T and U are, independently, hydrogen or lower alkyl.

98. (New) The method of claim 96, wherein P is



99. (New) The method of claim 80, wherein the administering is locally administering.

100. (New) The method of claim 80, wherein the administering is systemically administering.